# A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils

> **NCT02693769** · PHASE2,PHASE3 · TERMINATED · sponsor: **Mundipharma Research Limited** · enrollment: 2 (actual)

## Conditions studied

- ACOS (Fixed Airflow Obstruction and Elevated Eosinophils)

## Interventions

- **DRUG:** fluticasone propionate/formoterol fumarate breath actuated inhaler
- **DRUG:** Indacaterol maleate / glycopyrronium bromide capsules

## Key facts

- **NCT ID:** NCT02693769
- **Lead sponsor:** Mundipharma Research Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07
- **Primary completion:** 2016-10
- **Final completion:** 2016-12
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Recruitment issues
- **Last updated:** 2016-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02693769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02693769, "A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02693769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*